PDS Biotech Q2 Loss Misses Estimates as Cash Dwindles to $5.6M
PDSB is trading near its 52-week low of $0.23 (4.3% above the low) on elevated volume (6.0× avg).
Summary
PDS Biotech reported a Q2 net loss of $9.8M, or $0.18 per share, missing the $0.13 consensus. Operating expenses fell due to lower clinical trial, manufacturing, and personnel costs, but higher interest expenses from a non-cash debt retirement charge offset some of the savings. Cash dropped to $5.6M, leaving the company with limited runway as it pivots to PDS0301 and seeks a partner for PDS0101. This follows the August 11 announcement discontinuing the PDS0101 Phase 3 trial and the Nasdaq minimum bid price deficiency notice from July 31. The stock trades near its 52-week low at $0.24, and the company's $50M ATM program remains active, adding dilution risk.
At the time of this announcement, PDSB was trading at $0.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $0.23 to $1.55. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.